HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke

Natasha Shroff, Bradley Ander, Xinhua Zhan, Boryana Stamova, Da Liu, Heather Hull, Farah R. Hamade, Cheryl Dykstra-Aiello, Kwan Ng, Frank R Sharp, Glen C. Jickling

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The histone deacetylase 9 (HDAC9) polymorphism rs2107595 is associated with an increased risk for large vessel atherosclerotic stroke (LVAS). In humans, there remains a need to better understand this HDAC9 polymorphism’s contribution to large vessel stroke. In this pilot study, we evaluated whether the HDAC9 polymorphism rs2107595 is associated with differences in leukocyte gene expression in patients with LVAS. HDAC9 SNP rs2107595 was genotyped in 155 patients (43 LVAS and 112 vascular risk factor controls). RNA isolated from blood was processed on whole genome microarrays. Gene expression was compared between HDAC9 risk allele-positive and risk allele-negative LVAS patients and controls. Functional analysis identified canonical pathways and molecular functions associated with rs2107595 in LVAS. In HDAC9 SNP rs2107595 risk allele-positive LVAS patients, there were 155 genes differentially expressed compared to risk allele-negative patients (fold change > |1.2|, p < 0.05). The 155 genes separated the risk allele-positive and risk allele-negative LVAS patients on a principal component analysis. Pathways associated with HDAC9 risk allele-positive status involved IL-6 signaling, cholesterol efflux, and platelet aggregation. These preliminary data suggest an association with the HDAC9 rs2107595 risk allele and peripheral immune, lipid, and clotting systems in LVAS. Further study is required to evaluate whether these differences are related to large vessel atherosclerosis and stroke risk.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalTranslational Stroke Research
DOIs
StateAccepted/In press - Apr 13 2018

Fingerprint

Histone Deacetylases
Stroke
Gene Expression
Alleles
Single Nucleotide Polymorphism
Principal Component Analysis
Platelet Aggregation
Genes
Interleukin-6
Atherosclerosis
Leukocytes
Cholesterol
Genome
RNA
Lipids

Keywords

  • Atherosclerosis
  • Gene expression
  • Ischemic stroke
  • Large vessel stroke
  • Polymorphism
  • SNP

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke. / Shroff, Natasha; Ander, Bradley; Zhan, Xinhua; Stamova, Boryana; Liu, Da; Hull, Heather; Hamade, Farah R.; Dykstra-Aiello, Cheryl; Ng, Kwan; Sharp, Frank R; Jickling, Glen C.

In: Translational Stroke Research, 13.04.2018, p. 1-7.

Research output: Contribution to journalArticle

Shroff, Natasha ; Ander, Bradley ; Zhan, Xinhua ; Stamova, Boryana ; Liu, Da ; Hull, Heather ; Hamade, Farah R. ; Dykstra-Aiello, Cheryl ; Ng, Kwan ; Sharp, Frank R ; Jickling, Glen C. / HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke. In: Translational Stroke Research. 2018 ; pp. 1-7.
@article{d9e2865583074aac85302e3cb7cb9948,
title = "HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke",
abstract = "The histone deacetylase 9 (HDAC9) polymorphism rs2107595 is associated with an increased risk for large vessel atherosclerotic stroke (LVAS). In humans, there remains a need to better understand this HDAC9 polymorphism’s contribution to large vessel stroke. In this pilot study, we evaluated whether the HDAC9 polymorphism rs2107595 is associated with differences in leukocyte gene expression in patients with LVAS. HDAC9 SNP rs2107595 was genotyped in 155 patients (43 LVAS and 112 vascular risk factor controls). RNA isolated from blood was processed on whole genome microarrays. Gene expression was compared between HDAC9 risk allele-positive and risk allele-negative LVAS patients and controls. Functional analysis identified canonical pathways and molecular functions associated with rs2107595 in LVAS. In HDAC9 SNP rs2107595 risk allele-positive LVAS patients, there were 155 genes differentially expressed compared to risk allele-negative patients (fold change > |1.2|, p < 0.05). The 155 genes separated the risk allele-positive and risk allele-negative LVAS patients on a principal component analysis. Pathways associated with HDAC9 risk allele-positive status involved IL-6 signaling, cholesterol efflux, and platelet aggregation. These preliminary data suggest an association with the HDAC9 rs2107595 risk allele and peripheral immune, lipid, and clotting systems in LVAS. Further study is required to evaluate whether these differences are related to large vessel atherosclerosis and stroke risk.",
keywords = "Atherosclerosis, Gene expression, Ischemic stroke, Large vessel stroke, Polymorphism, SNP",
author = "Natasha Shroff and Bradley Ander and Xinhua Zhan and Boryana Stamova and Da Liu and Heather Hull and Hamade, {Farah R.} and Cheryl Dykstra-Aiello and Kwan Ng and Sharp, {Frank R} and Jickling, {Glen C.}",
year = "2018",
month = "4",
day = "13",
doi = "10.1007/s12975-018-0619-x",
language = "English (US)",
pages = "1--7",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",

}

TY - JOUR

T1 - HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke

AU - Shroff, Natasha

AU - Ander, Bradley

AU - Zhan, Xinhua

AU - Stamova, Boryana

AU - Liu, Da

AU - Hull, Heather

AU - Hamade, Farah R.

AU - Dykstra-Aiello, Cheryl

AU - Ng, Kwan

AU - Sharp, Frank R

AU - Jickling, Glen C.

PY - 2018/4/13

Y1 - 2018/4/13

N2 - The histone deacetylase 9 (HDAC9) polymorphism rs2107595 is associated with an increased risk for large vessel atherosclerotic stroke (LVAS). In humans, there remains a need to better understand this HDAC9 polymorphism’s contribution to large vessel stroke. In this pilot study, we evaluated whether the HDAC9 polymorphism rs2107595 is associated with differences in leukocyte gene expression in patients with LVAS. HDAC9 SNP rs2107595 was genotyped in 155 patients (43 LVAS and 112 vascular risk factor controls). RNA isolated from blood was processed on whole genome microarrays. Gene expression was compared between HDAC9 risk allele-positive and risk allele-negative LVAS patients and controls. Functional analysis identified canonical pathways and molecular functions associated with rs2107595 in LVAS. In HDAC9 SNP rs2107595 risk allele-positive LVAS patients, there were 155 genes differentially expressed compared to risk allele-negative patients (fold change > |1.2|, p < 0.05). The 155 genes separated the risk allele-positive and risk allele-negative LVAS patients on a principal component analysis. Pathways associated with HDAC9 risk allele-positive status involved IL-6 signaling, cholesterol efflux, and platelet aggregation. These preliminary data suggest an association with the HDAC9 rs2107595 risk allele and peripheral immune, lipid, and clotting systems in LVAS. Further study is required to evaluate whether these differences are related to large vessel atherosclerosis and stroke risk.

AB - The histone deacetylase 9 (HDAC9) polymorphism rs2107595 is associated with an increased risk for large vessel atherosclerotic stroke (LVAS). In humans, there remains a need to better understand this HDAC9 polymorphism’s contribution to large vessel stroke. In this pilot study, we evaluated whether the HDAC9 polymorphism rs2107595 is associated with differences in leukocyte gene expression in patients with LVAS. HDAC9 SNP rs2107595 was genotyped in 155 patients (43 LVAS and 112 vascular risk factor controls). RNA isolated from blood was processed on whole genome microarrays. Gene expression was compared between HDAC9 risk allele-positive and risk allele-negative LVAS patients and controls. Functional analysis identified canonical pathways and molecular functions associated with rs2107595 in LVAS. In HDAC9 SNP rs2107595 risk allele-positive LVAS patients, there were 155 genes differentially expressed compared to risk allele-negative patients (fold change > |1.2|, p < 0.05). The 155 genes separated the risk allele-positive and risk allele-negative LVAS patients on a principal component analysis. Pathways associated with HDAC9 risk allele-positive status involved IL-6 signaling, cholesterol efflux, and platelet aggregation. These preliminary data suggest an association with the HDAC9 rs2107595 risk allele and peripheral immune, lipid, and clotting systems in LVAS. Further study is required to evaluate whether these differences are related to large vessel atherosclerosis and stroke risk.

KW - Atherosclerosis

KW - Gene expression

KW - Ischemic stroke

KW - Large vessel stroke

KW - Polymorphism

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=85045283642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045283642&partnerID=8YFLogxK

U2 - 10.1007/s12975-018-0619-x

DO - 10.1007/s12975-018-0619-x

M3 - Article

C2 - 29651704

AN - SCOPUS:85045283642

SP - 1

EP - 7

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

ER -